The partnership aims at developing a complementary, semisynthetic, source of artemisinin, to improve the availability of high-quality artemisinin derivatives to drug manufacturers and contribute to stabilizing the price of artemisinin-containing antimalarials to benefit patients and payers. The original idea and the proof of concept were developed at the University of California-Berkeley, the project was then managed by the Institute for One World Health (IOWH), a nonprofit pharmaceutical company. From the proof of concept, a first chemical route was developed on a laboratory scale by Amyris Biotechnologies, a US based Biotech start-up. Sanofi was selected as the manufacturing partner, due to the malaria program within its Access to Medicines department, and because of its production and technological competences and capacity. The Bill & Melinda Gates Foundation (BMGF) provided significant financial support to this project, from its inception to its latest stages.
|Location||East Asia and Pacific, Zimbabwe, Zambia, Viet Nam, Uganda, Togo, Thailand, Tanzania, Swaziland, Sudan, Southern Sudan, South Africa, Somalia, Sierra Leone, Seychelles, Senegal, Sao Tome and Principe, Rwanda, Nigeria, Niger, Namibia, Myanmar, Mozambique, Mauritius, Mauritania, Mali, Malaysia, Malawi, Madagascar, Liberia, Lesotho, Laos, Kenya, Indonesia, India, Guinea-Bissau, Guinea, Ghana, Gambia, Gabon, Ethiopia, Eritrea, Equatorial Guinea, Cote d Ivoire, Congo, The Republic of, Congo, The Democratic Republic of, Comoros, Chad, Central African Republic, Cape Verde, Cameroon, Cambodia, Burundi, Burkina Faso, Botswana, Benin, Bangladesh, Angola, West Africa, Southern Africa, South Asia, Eastern Africa, Central Africa|